Moderna Inc. says its vaccine for respiratory syncytial virus, better known as RSV, could be ready for commercialization as soon as next year.
The Cambridge drugmaker is currently running a Phase 3 trial of its mRNA-based RSV vaccine. Data is expected sometime this winter; if it meets expectations, then Moderna could launch it before the fall 2023 sick season, executives said on the company's third-quarter earnings call Thursday morning.
WATCH ANYTIME FOR FREE
 |
>Stream NBC10 Boston news for free, 24/7, wherever you are. |
More on this story from Boston Business Journal
Get updates on what's happening in Boston to your inbox. Sign up for our >News Headlines newsletter.
Copyright Boston Business Journal
